Get the latest news, insights, and market updates on AMRX (Amneal Pharmaceuticals, Inc.). Explore the news page 4 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
Amneal Pharmaceuticals (AMRX) Profitability Milestone Tests Investor Optimism on Growth and Valuation
Amneal Pharmaceuticals (AMRX) has turned a key corner with a positive net profit margin for the first time after years of negative earnings growth, averaging -40.6% per year over the past five years. Revenue is forecast to increase at 7.4% per year, which is slower than the US market’s expected 10.3% pace. This gives investors both reason for optimism about newfound profitability and some caution about growth trajectory. See our full analysis for Amneal Pharmaceuticals. Now, let’s see how... Oct 31, 2025 - $AMRX
Amneal (NASDAQ:AMRX) Beats Q3 Sales Expectations, Stock Soars
Pharmaceutical company Amneal Pharmaceuticals (NASDAQ:AMRX) reported Q3 CY2025 results beating Wall Street’s revenue expectations, with sales up 11.7% year on year to $784.5 million. The company’s full-year revenue guidance of $3.05 billion at the midpoint came in 1.3% above analysts’ estimates. Its non-GAAP profit of $0.17 per share was 22.9% above analysts’ consensus estimates. Oct 30, 2025 - $AMRX
Amneal: Q3 Earnings Snapshot
On a per-share basis, the Bridgewater, New Jersey-based company said it had net income of 1 cent. Earnings, adjusted for one-time gains and costs, came to 17 cents per share. The results exceeded Wall Street expectations. Oct 30, 2025 - $AMRX
Amneal (AMRX) Reports Q3 Earnings: What Key Metrics Have to Say
While the top- and bottom-line numbers for Amneal (AMRX) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values. Oct 30, 2025 - $AMRX
Amneal Reports Third Quarter 2025 Financial Results
‒ Q3 2025 Net Revenue of $785 million; GAAP Net Income of $2 million; Diluted Income per Share of $0.01 ‒‒ Adjusted EBITDA of $160 million; Adjusted Diluted EPS of $0.17 ‒‒ Updated 2025 Full Year Guidance ‒ BRIDGEWATER, N.J., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced its results for the third quarter ended September 30, 2025. “Amneal delivered another strong quarter and updated our 2025 outlook, underscoring the stre Oct 30, 2025 - $AMRX
Amneal Receives U.S. FDA Tentative Approval for Beclomethasone Dipropionate HFA Inhalation Aerosol
Company’s first metered-dose inhalation (MDI) product and establishes a new growth vector for the Affordable Medicines segmentBRIDGEWATER, N.J., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) today announced that the U.S. Food and Drug Administration (FDA) has tentatively approved the Company’s Abbreviated New Drug Application (ANDA) for beclomethasone dipropionate HFA inhalation aerosol (40 mcg/actuation and 80 mcg/actuation). The product is the gener Oct 29, 2025 - $AMRX
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" to help us understand site usage and improve the platform.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple